Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population

被引:6
作者
Mattingly, T. Joseph, II [1 ]
Pandit, Neha S. [1 ]
Onukwugha, Eberechukwu [2 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv, Baltimore, MD 21201 USA
关键词
Burden-of-illness; Co-infection; Cost-of-illness; Hepatitis C; HIV; HEALTH; INFECTION; SOFOSBUVIR; DISEASE; ACCESS; HIV;
D O I
10.1007/s40121-019-0240-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: In patients with hepatitis C virus (HCV), human immunodeficiency virus (HIV) represents a major cause of morbidity and economic burden. Economic evaluations in HIV-HCV typically focus on government-sponsored insurance plans rather than a commercially insured cohort. This study evaluated the clinical and economic burden of HIV-HCV co-infection compared with HCV alone in commercially insured patients throughout the United States. Methods: Commercial medical and pharmacy claims from 2007 to 2015 from a 10% random sample of enrollees within the IQVIA PharMetrics Plus administrative claims database were analyzed. Patients were included based on the presence of a claim with a HCV diagnosis across three separate cross-sectional periods which were created from the full dataset (2007-2009, 2010-2012, and 2013-2015). Costs incurred were categorized as emergency department, inpatient, outpatient medical, outpatient pharmacy, and other, based on the claim place of service. Descriptive statistics and proportion of total costs in each group have been reported for all cost categories. Results: The samples included 22,329 from 2007 to 2009, 23,186 from 2010 to 2012, and 27,288 from 2013 to 2015. In all three cross-sections, HIV-HCV individuals were more likely to be male and carriers of hepatitis B virus. Pharmacy costs were $29,368 in the HCV-only group, compared to $73,547 in the HIV-HCV group (p < 0.0001). Pharmacy costs increased as a proportion of total costs for both groups, increasing after 2012 from 41% to 55% for HIV-HCV and from 19% to 34% for HCV-only. Conclusion: The present study describes the total direct health care costs in HIV-HCV co-infected individuals and HCV-only patients in commercially insured health plans. Spending on pharmacy increased as a proportion of total health care costs in both groups. Further clinical and economic evaluations in HCV and/or HIV populations in the US should consider system-level factors related to insurance type when applying to the entire population.
引用
收藏
页码:219 / 228
页数:10
相关论文
共 29 条
[1]   Cost-of-illness studies - A review of current methods [J].
Akobundu, Ebere ;
Ju, Jing ;
Blatt, Lisa ;
Mullins, C. Daniel .
PHARMACOECONOMICS, 2006, 24 (09) :869-890
[2]   Insurance Type and Access to Health Care Providers and Appointments Under the Affordable Care Act [J].
Alcala, Hector E. ;
Roby, Dylan H. ;
Grande, David T. ;
McKenna, Ryan M. ;
Ortega, Alexander N. .
MEDICAL CARE, 2018, 56 (02) :186-192
[3]   Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States [J].
Barua, Soumitri ;
Greenwald, Robert ;
Grebely, Jason ;
Dore, Gregory J. ;
Swan, Tracy ;
Taylor, Lynn E. .
ANNALS OF INTERNAL MEDICINE, 2015, 163 (03) :215-+
[4]   A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System [J].
Beperio, Pamela S. ;
Mole, Larry A. ;
Backus, Lisa I. ;
Ross, David ;
Neuhauser, Melinda M. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (06) :533-+
[5]   Hepatitis C virus infection in the human immunodeficiency virus infected patient [J].
Clausen, Louise Nygaard ;
Lundbo, Lene Fogt ;
Benfield, Thomas .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (34) :12132-12143
[6]   Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study [J].
Clements, Karen M. ;
Clark, Robin E. ;
Lavitas, Pavel ;
Kunte, Parag ;
Graham, Camilla S. ;
O'Connell, Elizabeth ;
Lenz, Kimberly ;
Jeffrey, Paul .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (06) :714-722
[7]   Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population [J].
Davis, Keith L. ;
Mitra, Debanjali ;
Medjedovic, Jasmina ;
Beam, Cynthia ;
Rustgi, Vinod .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 (02) :E17-E24
[8]   Extent of illicit drug use and dependence, and their contribution to the global burden of disease [J].
Degenhardt, Louisa ;
Hall, Wayne .
LANCET, 2012, 379 (9810) :55-70
[9]  
DO A, 2015, DOAMITTAL Y, V10, P1
[10]   Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States [J].
Dunn, Abe ;
Grosse, Scott D. ;
Zuvekas, Samuel H. .
HEALTH SERVICES RESEARCH, 2018, 53 (01) :175-196